相似文献
1
Harnessing heterogeneity in type 2 diabetes mellitus.
Nat Rev Endocrinol. 2020 Feb;16(2):79-80. doi: 10.1038/s41574-019-0308-1.
2
Moving towards a more precise treatment of diabetes.
Lancet Diabetes Endocrinol. 2015 Mar;3(3):171. doi: 10.1016/S2213-8587(15)00010-8.
3
Personalized medicine of type 2 diabetes.
Front Med. 2013 Mar;7(1):1-3. doi: 10.1007/s11684-013-0241-y.
4
Treatment of Mitochondrial Diabetes with a Peroxisome Proliferator-activated Receptor (PPAR)-gamma Agonist.
Intern Med. 2016;55(9):1143-7. doi: 10.2169/internalmedicine.55.4418. Epub 2016 May 1.
5
Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists on glycemic control, lipid profile and cardiovascular risk.
Curr Mol Pharmacol. 2012 Jun;5(2):272-81. doi: 10.2174/1874467211205020272.
6
PPAR-γ action: it's all in your head.
Nat Med. 2011 May;17(5):544-5. doi: 10.1038/nm0511-544.
7
Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus?
Diabetes Obes Metab. 2013 Nov;15(11):967-77. doi: 10.1111/dom.12101. Epub 2013 Apr 18.
8
Future directions for insulin sensitizers in disease prevention.
Curr Opin Investig Drugs. 2007 Sep;8(9):707-10.
9
Advances on PPARγ Research in the Emerging Era of Precision Medicine.
Curr Drug Targets. 2018;19(6):663-673. doi: 10.2174/1389450118666170622091333.
10
Discovery and development of selective PPAR gamma modulators as safe and effective antidiabetic agents.
Expert Opin Investig Drugs. 2010 Apr;19(4):489-512. doi: 10.1517/13543781003640169.
引用本文的文献
1
Discovery of a novel binding pocket in PPARγ for partial agonists: structure-based virtual screening identifies ginsenoside Rg5 as a partial agonist promoting beige adipogenesis.
Front Chem. 2025 May 8;13:1579445. doi: 10.3389/fchem.2025.1579445. eCollection 2025.
2
Updates of precision medicine in type 2 diabetes.
Camb Prism Precis Med. 2023 Apr 14;1:e24. doi: 10.1017/pcm.2023.12. eCollection 2023.
3
Whole-exome sequencing in familial type 2 diabetes identifies an atypical missense variant in the RyR2 gene.
Front Endocrinol (Lausanne). 2024 Feb 20;15:1258982. doi: 10.3389/fendo.2024.1258982. eCollection 2024.
4
Label-free quantitative proteomics analysis for type 2 diabetes mellitus early diagnostic marker discovery using data-independent acquisition mass spectrometry (DIA-MS).
Sci Rep. 2023 Nov 27;13(1):20880. doi: 10.1038/s41598-023-48185-3.
5
Unsupervised Anomaly Detection to Characterize Heterogeneity in Type 2 Diabetes.
AMIA Jt Summits Transl Sci Proc. 2023 Jun 16;2023:32-41. eCollection 2023.
6
Prioritization of genes associated with type 2 diabetes mellitus for functional studies.
Nat Rev Endocrinol. 2023 Aug;19(8):477-486. doi: 10.1038/s41574-023-00836-1. Epub 2023 May 11.
7
Trialing precision medicine for type 2 diabetes.
Nat Med. 2023 Feb;29(2):309-310. doi: 10.1038/s41591-022-02168-5.
8
Cluster analysis of Thai patients with newly diagnosed type 2 diabetes mellitus to predict disease progression and treatment outcomes : A prospective cohort study.
BMJ Open Diabetes Res Care. 2022 Dec;10(6). doi: 10.1136/bmjdrc-2022-003145.
9
The Potential Roles of Post-Translational Modifications of PPARγ in Treating Diabetes.
Biomolecules. 2022 Dec 8;12(12):1832. doi: 10.3390/biom12121832.
10
Understanding islet dysfunction in type 2 diabetes through multidimensional pancreatic phenotyping: The Human Pancreas Analysis Program.
Cell Metab. 2022 Dec 6;34(12):1906-1913. doi: 10.1016/j.cmet.2022.09.013. Epub 2022 Oct 6.
Zotero 插件